More Sit-to-Stand Transitions May Lower Blood Pressure in Postmenopausal Women: Study

A new study published in Circulation has revealed that increasing the number of daily sit-to-stand transitions can significantly lower diastolic blood pressure in postmenopausal women with overweight or obesity, offering a simple, low-cost strategy to improve cardiovascular health.

Researchers found that participants who performed more frequent sit-to-stand movements throughout the day experienced measurable reductions in diastolic blood pressure, even without additional structured exercise.

The findings highlight the potential benefits of reducing sedentary behavior by incorporating small, frequent bouts of movement into daily routines, particularly for populations at elevated cardiovascular risk. Postmenopausal women often experience increased blood pressure due to hormonal changes, weight gain, and reduced physical activity, making these results especially relevant. By simply standing up from a seated position multiple times a day, individuals may enhance vascular function and lower cardiovascular disease risk.

The authors emphasize that these sit-to-stand transitions are easy to implement in most settings, including at home or work, and can be combined with other healthy lifestyle interventions for greater impact. However, they note that further studies are needed to assess the long-term effects and optimal frequency of these movements. This research supports public health messages encouraging less sitting and more movement as an achievable way to improve heart health.

Reference:
Clarke, J., et al. (2024). Effects of daily sit-to-stand transitions on blood pressure in postmenopausal women with overweight or obesity. Circulationhttps://doi.org/10.1161/CIRCULATIONAHA.124.073385

Powered by WPeMatico

Lebrikizumab Shows Strong Efficacy and Safety in Atopic Dermatitis: Study

Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease that significantly impacts quality of life and often requires systemic therapies for patients with moderate-to-severe disease. With increasing focus on targeted biologic therapies, anti–IL-13 monoclonal antibodies have emerged as a promising treatment option for patients inadequately controlled with conventional therapies.

Findings from the BIOREP registry have highlighted that lebrikizumab achieved significant improvement in atopic dermatitis, with 63.7% of patients reaching an EASI-75 response at 16 weeks. The benefit was especially pronounced in treatment-naïve patients compared to those previously exposed to biologics. The therapy also demonstrated a favorable safety profile, with sustained efficacy documented through 24 weeks. Registry data showed that lebrikizumab not only improved objective disease severity scores but also enhanced patient-reported outcomes such as pruritus reduction and quality of life measures. Rates of adverse events remained low, with conjunctivitis and injection-site reactions being the most commonly reported but generally mild. No new safety concerns were identified during the observation period. The study authors emphasized the importance of early initiation, noting that biologic-naïve patients responded more robustly than previously treated patients. This suggests that earlier use of lebrikizumab may maximize clinical benefit and minimize disease burden. In addition, the durability of response over 24 weeks supports its potential as a long-term management option in clinical practice.

As the treatment landscape for atopic dermatitis continues to expand, real-world registry data such as BIOREP provide valuable evidence on the efficacy and safety of emerging biologics beyond controlled clinical trials. The findings reinforce lebrikizumab as a strong therapeutic candidate for patients with moderate-to-severe AD who require systemic intervention.

Reference
Martínez-García, G., Rossi, A., & Chen, Y. (2025). Real-world effectiveness and safety of lebrikizumab in moderate-to-severe atopic dermatitis: Findings from the BIOREP registry. Journal of the American Academy of Dermatology, 92(3), 415–424. https://doi.org/10.1016/j.jaad.2025.01.045

Keywords: lebrikizumab, atopic dermatitis, EASI-75, BIOREP registry, biologic therapy, IL-13 inhibitor, treatment-naïve, real-world data, safety profile, dermatology

Powered by WPeMatico

Nonsurgical Periodontal Therapy Helps Improve Blood Sugar Control in Type 2 Diabetes, Study Finds

Netherlands: A new longitudinal study published in the Journal of Dental Research has found that nonsurgical periodontal therapy (NSPT) not only improves gum health but also significantly lowers blood sugar levels in patients with type 2 diabetes (T2D), particularly in those with poor baseline glycemic control

The research, led by H.K. Chee from the Center for Dentistry and Oral Hygiene, University Medical Center Groningen, University of Groningen, Netherlands, explored the long-term effects of periodontal treatment on HbA1c levels while accounting for changes in diabetes medications—an aspect that many earlier short-term studies overlooked.
The study followed 154 nonsmoking patients with T2D and periodontitis who received NSPT. Treatment involved professional plaque removal, subgingival instrumentation, root surface debridement, and oral hygiene instructions at baseline, with maintenance care and repeated subgingival therapy provided at 3, 6, 9, and 12 months. Full-mouth periodontal assessments were conducted at each follow-up, measuring plaque accumulation, bleeding on probing, gingival suppuration, attachment loss, and periodontal inflamed surface area (PISA). Glycemic control was tracked through point-of-care HbA1c testing at each visit, supplemented with HbA1c records from the year preceding treatment.
At baseline, the average HbA1c level was 8.4% ± 1.6%. Following treatment, participants demonstrated consistent and sustained improvements in glycemic control. HbA1c decreased by 0.70%, 0.73%, 0.68%, and 0.77% at 3, 6, 9, and 12 months, respectively. Notably, those with poorer baseline control (HbA1c >8.0%) experienced the greatest improvement, with an average 1.31% reduction at 12 months compared to just 0.24% in patients who began with HbA1c ≤8.0%.
Periodontal health also showed marked improvement over the study period. PISA was reduced by 352.7 mm² after 12 months, while clinical attachment loss, probing pocket depth, and bleeding scores all significantly improved by the three-month follow-up and were sustained through the year.
Key Findings
  • Average HbA1c dropped by about 0.7% at 3, 6, 9, and 12 months after periodontal treatment.
  • Patients with baseline HbA1c >8.0% showed the greatest benefit, with a 1.31% reduction at 12 months.
  • Periodontal inflamed surface area (PISA) decreased by 352.7 mm² after 12 months.
  • Clinical attachment loss, probing pocket depth, and bleeding scores improved at 3 months and were sustained throughout the year.
“These results highlight the important systemic benefits of periodontal therapy beyond oral health alone,” the authors noted. “Nonsurgical periodontal treatment, when combined with ongoing maintenance, can play a valuable role in improving metabolic control among individuals with type 2 diabetes.”
The findings support the growing evidence of a strong link between periodontal disease and systemic health outcomes, suggesting that managing gum inflammation may have significant implications for diabetes care. While the study was observational, the results align with clinical insights that addressing chronic inflammation through periodontal care can improve glycemic outcomes.
“NSPT led to lasting improvements in both periodontal status and glycemic control over 12 months in patients with T2D. The benefits were especially pronounced in those with poor initial diabetes control, underscoring the importance of integrating oral health care into comprehensive diabetes management strategies,” the authors concluded.
Reference:
Chee, H. K., Tan, H. X., Tjakkes, H. E., Vissink, A., & Seneviratne, C. J. Long-Term Effect of Periodontal Therapy on HbA1c Changes in Type 2 Diabetes. Journal of Dental Research. https://doi.org/10.1177_00220345251357875

Powered by WPeMatico

Cholecystectomy Linked to Higher Risk of MASLD, Especially in Patients with Multiple Metabolic Risk Factors: Study

South Korea: A large population-based study from South Korea has revealed a significant association between cholecystectomy—the surgical removal of the gallbladder—and an elevated risk of developing metabolic dysfunction-associated steatotic liver disease (MASLD), particularly in individuals with multiple cardiometabolic risk factors.

The research, conducted by Dr. Hyuk Soo Eun and colleagues from the Department of Internal Medicine at Chungnam National University School of Medicine, has been published in Scientific Reports.

The investigators analyzed data from over 660,000 participants enrolled in the Korean National Health Insurance Service-National Sample Cohort between 2009 and 2019. Among them, 4,664 individuals who had undergone cholecystectomy were matched with controls based on age, sex, and other parameters. The presence of MASLD was determined using the fatty liver index (FLI), a validated non-invasive tool for assessing liver fat accumulation.

The study found the following:

  • Individuals who had undergone cholecystectomy faced a 1.48 times higher risk of developing MASLD compared to those who had not undergone the procedure.
  • The risk of MASLD significantly increased in individuals with three or more cardiometabolic risk factors.
  • These risk factors included obesity or high waist circumference, elevated fasting glucose or diabetes, hypertension, high triglyceride levels, and low HDL cholesterol.
  • In individuals with three or more such risk factors, the risk of MASLD rose more than fivefold (adjusted hazard ratio: 5.26).
  • In contrast, those with fewer than three cardiometabolic risk factors had only a modest increase in MASLD risk (1.22-fold).

These findings emphasize the role of underlying metabolic health in determining post-cholecystectomy outcomes. According to the researchers, preoperative evaluation of cardiometabolic risk profiles is crucial in patients scheduled for gallbladder removal. The study recommends that individuals with multiple risk factors undergo careful assessment and be counseled on their elevated risk of developing MASLD after surgery.

While the study’s results are robust due to its large sample size and stratified risk analysis, the authors acknowledge certain limitations. MASLD was diagnosed using the fatty liver index rather than liver biopsy, which remains the gold standard. However, given the impracticality of performing liver biopsies or MRI scans in large-scale cohorts, the FLI was deemed a suitable and validated alternative.

The study also highlights the potential for residual confounding despite statistical adjustments, as well as limited generalizability beyond South Korea due to the ethnically homogenous population studied. Moreover, patients who underwent cholecystectomy may have received more frequent follow-up care, introducing a degree of surveillance bias.

“Our findings add to the growing body of evidence linking cholecystectomy to adverse metabolic outcomes. The risk of MASLD is particularly elevated in patients with multiple cardiometabolic risk factors, highlighting the importance of proactive risk assessment and management before and after gallbladder surgery. Clinicians should closely monitor liver health in these individuals and implement aggressive strategies to control metabolic risk factors postoperatively,” stated Dr. Hyuk Soo Eun and colleagues.

Reference:

Jeon, H. J., Eun, H. S., Rou, W. S., Kim, S. H., Lee, B. S., & Ahn, S. (2025). Association between cholecystectomy and the risk of new-onset metabolic dysfunction-associated steatotic liver disease: A risk-stratified cohort study. Scientific Reports, 15(1), 1-12. https://doi.org/10.1038/s41598-025-13556-5

Powered by WPeMatico

Vision loss, damage could be tied to eye pressure, study finds

One of the world’s leading causes of irreversible vision loss could begin with elevated eye pressure, according to a recent study published in the American Academy of Ophthalmology.

Yi Hua, a biomedical engineering professor at the University of Mississippi, partnered with researchers at the University of Pittsburgh to study how ocular hypertension – elevated eye pressure – affects the eye.

“We wanted to see how intraocular pressure changes and deforms the blood vessels in the eye,” Hua said. “If we can understand that, we can inform drug delivery to improve blood flow in the back of the eye. That can slow down the progression of glaucoma.”

Glaucoma damages the optic nerve, leading to irreversible vision loss. It is a leading cause of blindness worldwide. Glaucoma is sometimes called the “silent thief of sight,” with symptoms often not becoming apparent until the damage is extensive.

“This can lead us to a new way to diagnose glaucoma earlier,” said Yuankai Lu, a postdoctoral researcher at the University of Pittsburgh and co-author of the study. “If this finding holds true, then we can use blood flow supply to predict the development of this disease.”

Pressure inside the eye can increases when aqueous humor – a clear fluid produced by the eye – does not properly drain. The buildup of fluid increases pressure on the lamina cribrosa, a mesh-like structure in the optic nerve head, which can constrict blood vessels, reducing oxygen flow to nerve cells and other parts of the eye.

Without oxygen, these cells can die, leading to loss of sight.

“We want to understand this problem so we can develop new drug pathways for patients,” Hua said. “We still do not have an efficient way to slow down the progression of glaucoma. The only way is to reduce eye pressure.

“But for some patients, even though we’ve reduced the eye pressure, the damage progresses, and they still lose vision. So, we need better methods.”

The researchers used a combination of 3D modeling and fluorescent dye to trace the path of blood flow through the eye under various amounts of pressure. They found even mildly elevated eye pressure can distort blood vessels and lead to hypoxia, an oxygen deficit. Extreme eye pressure led to hypoxia in approximately 30% of the lamina cribrosa tissue.

“The eye can weather a short-lived increase in eye pressure,” said Ian Sigal, associate professor of ophthalmology and bioengineering at the University of Pittsburgh. “For instance, when we rub our eyes lightly. But a chronic increase of weeks, months or years can cause substantial damage.

“The vision loss resulting from this damage cannot be recovered. Hence, it is crucial to find ways to detect the disease and prevent the damage before it happens.”

Previous research has correlated elevated eye pressure with glaucoma, but did not explain how those issues were related, Lu said.

“Most glaucoma research is based on statistics, which can give you a correlation,” he said. “But it was actually very difficult to discover the mechanics of it.

“By combining imaging techniques with 3D modeling, we gained a more comprehensive understanding of blood flow and oxygen distribution in the eye.”

Treatment options are available for elevated eye pressure, but they are most effective for patients who undergo regular eye examinations and are diagnosed early, especially if they are at risk of developing glaucoma, Hua said.

Risk factors include medical conditions like high blood pressure or diabetes, a family history of the disease and race, as studies show that Black and Latino individuals are more likely to be affected.

“We really want to raise awareness of this issue,” Hua said. “A lot of people know the risk of high blood pressure, but we want to also raise the importance of elevated eye pressure.” 

Reference:

Yuankai Lu, Impact of Elevated Intraocular Pressure on Lamina Cribrosa Oxygenation: A Combined Experimental–Computational Study on Monkeys, Ophthalmology Science, DOI10.1016/j.xops.2025.100725 

Powered by WPeMatico

Artificial intelligence-based screening of breast cancer by mammography microcalcification accurate: Study

Each year, millions of women undergo mammography to screen for breast cancer, yet tiny calcium specks-known as microcalcifications-often evade detection or are misread, leading to delayed diagnoses or unnecessary biopsies. Conventional computer-aided tools rely on hand-crafted rules and struggle with the sheer variety of imaging devices and lesion patterns.

In a recent study led by Dr. Ke-Da Yu from Fudan University Shanghai Cancer Center, a novel deep-learning approach that automatically finds and classifies microcalcifications across different machines and patient populations was developed-bringing both accuracy and consistency to breast-cancer screening.

“Microcalcifications can be just a few pixels wide. Hence, spotting them amid normal tissue is like finding a needle in a haystack,” explains Dr. Yu. “We wanted a system that adapts to any mammogram and never overlooks early warning signs.”

The team’s innovation rests on two key advances:

• Adaptive, multi-scale detection: By integrating a faster region-based convolutional neural network (R-CNN) model with a feature-pyramid network (FPN), the pipeline fuses features at multiple resolutions-enabling it to localize both coarse clusters and individual specks without any manually tuned thresholds.

• Robust, multi-center training: Trained on 4,810 biopsy-confirmed mammograms (6,663 lesions evenly split between benign and malignant) from three hospitals, the system automatically standardizes each image, so it works seamlessly across different scanners and clinical settings.

In blind testing, the pipeline processed each mammogram, achieving approximately 75% overall accuracy at the microcalcification-lesion level with 76% sensitivity for malignant lesions and about 72% accuracy at the breast level.

“This solution can be deployed directly on standard radiology workstations,” adds Dr. Yu. “By pre-marking suspicious regions on each mammogram, it enables radiologists to quickly focus on areas of concern, significantly reducing both missed diagnoses and unnecessary biopsies-thereby easing patient discomfort and lowering healthcare costs.”

The research team has open-sourced the code, and their next steps will focus on integrating the system into clinical workflows, with the aim of offering a reliable AI-driven tool for more widespread breast-cancer screening.

Reference:

Qing Lin, Wei-Min Tan, Jing-Yu Ge, Yan Huang, Qin Xiao, Ying-Ying Xu, Yi-Ting Jin, Zhi-Ming Shao, Ya-Jia Gu, Bo Yan, Ke-Da Yu, Artificial intelligence-based diagnosis of breast cancer by mammography microcalcification, Fundamental Research https://doi.org/10.1016/j.fmre.2023.04.018.

Powered by WPeMatico

Low-intensity extracorporeal shock wave therapy ineffective for Post-Prostatectomy Erectile Dysfunction: Study

A new study published in The Journal of Urology found that low-intensity extracorporeal shock wave therapy (LI-SWT) did not significantly improve erectile dysfunction (ED) in men post-radical prostatectomy when compared to a sham procedure. Fewer than 20% of men in the LI-SWT group achieved erections sufficient for sexual intercourse. 

Even with nerve-sparing procedures, ED is still a serious side effect following radical prostatectomy. According to a 2009 meta-analysis, 58% of patients recovered their erectile function overall following prostatectomy, meaning that a sizable portion of patients still experienced ED after the procedure.

Due to the poor efficacy of current therapies, innovative strategies are desperately needed. For many years, a variety of medical specialties have employed extracorporeal shock wave treatment (ESWT). By encouraging neoangiogenesis and nerve regeneration, low-intensity extracorporeal shock wave treatment has demonstrated potential for vasculogenic ED.

Furthermore, there is evidence that shock wave treatment may enhance the way phosphodiesterase type 5 inhibitors work. Although there is little research on LI-SWT’s effects following prostatectomy, the findings are promising. The precise mode of action is still uncertain, though. Thus, to fill a significant need in the available rehabilitation alternatives, this study assessed whether LI-SWT might enhance erectile function in individuals who had undergone a prostatectomy.

A total of 75 subjects in all were randomly assigned to either LI-SWT or a sham therapy. A zero-inflated negative binomial model was used to assess the IIEF scores, and suitable nonparametric techniques, such as binary transformation for clinically significant outcomes, were used to the ordinal EHS data.

With a ratio of 1.2 (95% CI: 0.1-2.4, P =.469), the zero-inflated model for IIEF scores revealed no discernible difference between treatment groups. The LI-SWT group’s estimated median IIEF score at 24 weeks after treatment was 4, whereas the sham group’s was 4. With median scores at 24 weeks of 2 in the LI-SWT group compared to 2 in the sham group, there was no discernible treatment benefit for EHS.

At 24 weeks, 18% (95% CI: 9%-34%) of patients in the LI-SWT group and 26% (95% CI: 14%-43%) of patients in the sham group had sufficient erection hardness (EHS ≥3) (P =.552). Overall, the results support that LI-SWT is not likely to be a successful therapeutic option for ED following a prostatectomy. 

Reference:

Pedersen, T. B., Secher, C., Moumneh, A., Hvid, N., Lund, M., Fojecki, G., & Lund, L. (2025). A prospective randomized study on low-energy extracorporeal shock wave therapy for erectile dysfunction after radical prostatectomy. The Journal of Urology, 214(2), 156–166. https://doi.org/10.1097/JU.0000000000004576

Powered by WPeMatico

Metformin may Prevent Recurrence of Hyperemesis Gravidarum among those with prior history: Study

Researchers have found in a new study that Metformin, commonly used before and during pregnancy, may offer a safe and cost-effective option to reduce the recurrence of hyperemesis gravidarum in patients with a prior history. However further clinical trials were needed to validate its preventive use before conception to improve outcomes for both mother and child.

Severe nausea and vomiting of pregnancy and hyperemesis gravidarum are associated with adverse maternal, fetal, and child outcomes. The recurrence risk is reported to be as high as 89%. Identifying an effective, safe, and affordable method to prevent hyperemesis gravidarum is critical to reducing risk of reoccurrence and improving maternal, fetal, and child health. We recently demonstrated that genetic predisposition to hyperemesis gravidarum is mediated by low pre-pregnancy levels of the emetogenic hormone Growth and Differentiation Factor 15, resulting in hypersensitivity to its rapid rise during pregnancy. Because metformin increases circulating levels of the Growth and Differentiation Factor 15, we hypothesized that use of metformin before pregnancy will desensitize patients to the hormone and lower the risk of severe nausea and vomiting in pregnancy and hyperemesis gravidarum.

The objective of the study is to determine whether daily use of metformin is associated with lower risk of severe nausea and vomiting of pregnancy and hyperemesis gravidarum. By structured questionnaire, visitors to the Hyperemesis Gravidarum Education and Research Foundation social media sites from January 2023 to September 2024 reported daily use of 32 common substances in the month before each pregnancy and level of nausea and vomiting of pregnancy. Crude and multivariate associations between use of each substance and severe nausea and vomiting of pregnancy/hyperemesis gravidarum in the subsequent pregnancy were estimated by logistic regression. Final multivariate models included tobacco use and maternal age; number and type of additional drugs used, and race/ethnicity had little influence and were not retained. Results: A total of 5414 participants reported on daily medication/substance use in the month prior to pregnancy and level of nausea and vomiting during pregnancy. Using metformin before the first pregnancy was associated with >70% reduction of risk of hyperemesis gravidarum [aRR=0.29 (95%CI=0.12-0.71, P=0.007,]. Tobacco use was also associated with a significant reduction of risk [aRR=0.51 (95%CI=0.30-0.86), P=0.011]. Conversely, selective serotonin reuptake inhibitors were associated with an increased risk of hyperemesis gravidarum [aRR=2.41 (95%CI=1.33-4.38), P=0.004]. Use of metformin was also associated with an 82% reduction in risk of severe nausea and vomiting of pregnancy/hyperemesis gravidarum [aOR=0.18 (0.06-0.59), P=0.005] in the 2nd pregnancy, even after adjustment for the 86% recurrence risk identified in this study. Conversely, use of cannabis or selective serotonin reuptake inhibitors prior to the second pregnancy were each associated with increased risk [aOR=3.48 (1.80-6.75), P<0.001]; aOR=1.84 (1.12-3.04), P=0.016]. Pre-pregnancy metformin treatment may decrease risk of severe nausea and vomiting, while pre-pregnancy cannabis use and/or selective serotonin reuptake inhibitors may increase risk. Metformin, which is routinely used pre and post conception, may be a safe and affordable treatment to offer patients with a prior history of hyperemesis gravidarum to decrease the chance of recurrence. Clinical trials are warranted to investigate metformin use prior to pregnancy to lower hyperemesis gravidarum risk, thereby mitigating the associated adverse maternal and offspring outcomes.

Reference:

Pre-pregnancy metformin use associated with lower risk of severe nausea and vomiting of pregnancy and hyperemesis gravidarum. Sharma, Neelu et al. American Journal of Obstetrics & Gynecology, Volume 0, Issue 0

Keywords:

Metformin, Prevent, Recurrence, Hyperemesis, Gravidarum, among, prior history, Study, American Journal of Obstetrics & Gynecology , Cannabis, growth and differentiation factor 15, GDF15, hyperemesis gravidarum, metformin, morning sickness, nausea, pregnancy, prevention, selective serotonin reuptake inhibitors, vomiting

Powered by WPeMatico

Rs 180 Crore Ozempic Fraud: LOC Issued Against Pharma Firm CEO

New Delhi: Delhi Police has issued a lookout circular (LOC) against Vicky Ramancha, Chief Executive Officer (CEO) of a pharmaceutical company, for allegedly duping a US-based firm of over Rs 180 crore in a fraudulent Ozempic supply deal.

According to a recent media report in The Indian Express, officials said Ramancha misled Assure Global LLC, an American company, by projecting his political connections and government links in India to gain their confidence. The LOC was issued last week.

The case dates back to July 2023, when Ramancha’s subsidiary, R & R Global Procurement Corporation, signed an agreement with Assure Global to supply 1.25 lakh doses of Ozempic, allegedly sourced from China. However, Ozempic—an injectable semaglutide drug prescribed for Type-2 diabetes—is manufactured exclusively by Novo Nordisk in Denmark.

Assure Global initially filed a complaint with Delhi Police in August 2024, but with no action taken for several months, the company approached Patiala House Court through advocate Namit Saxena. On May 29, 2025, the court directed that an FIR be registered within 24 hours. Following this order, on June 3, police registered a case against Ramancha under Sections 420 (cheating), 406 (criminal breach of trust), and 120B (criminal conspiracy) of the IPC.

Ramancha, who described himself in court as a non-resident Indian (NRI) between July 2023 and July 2024, sought to have the FIR quashed but his plea was rejected. On August 11, his anticipatory bail petition was also dismissed by Additional Sessions Judge Saurabh Pratap Singh Laler.

The FIR states that between September 13 and December 15, 2023, Assure Global made seven payments amounting to $18.83 million (around Rs 156 crore) to Ramancha’s firms under two sale-purchase deeds. Despite assurances, the first consignment of 20,000 Ozempic units never arrived. Instead, according to investigators, the accused relied on bogus contracts, relabeled drugs, and notarised documents from Patiala House Court to lend legitimacy to the fraudulent transactions.

Police stated that multiple summons sent to Ramancha’s Goregaon West, Mumbai address were returned undelivered, and he also shifted addresses between court filings.

TIE reports that according to the Economic Offences Wing (EOW), “Ramancha had used notarised documents from Patiala House Court to lend legitimacy to fraudulent agreements.” The FIR further adds that the fraud was carried out through bogus sale-purchase deeds and the supply of fake or relabeled medicines. The complaint filed by Assure Global also names “an authorised representative (for Ramancha) residing in New Delhi.

Also Read: Orthopaedic Surgeon arrested for Rs 1.41 lakh gold fraud

Powered by WPeMatico

New malaria drug for babies offers hope to health workers in Uganda

Alice Nekesa did not know she was infected with malaria-causing parasites until it was too late. She was in the fourth month of pregnancy last year when she started bleeding, a miscarriage later attributed to untreated malaria in her.

Powered by WPeMatico